S-1/A: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants

Aptevo Therapeutics is launching a public offering of common stock, pre-funded warrants, and common stock purchase warrants to raise capital for working capital and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is undertaking a public offering of up to 12,987,013 shares of common stock, along with Series A and Series B warrants to purchase additional shares.
• Pre-funded warrants are also being offered to investors who would exceed beneficial ownership limits with direct share purchases.
• Each share of common stock (or pre-funded warrant) comes with one Series A warrant and one Series B warrant.
• The Series A warrants expire five years from the date of stockholder approval and the Series B warrants expire two and a half years from the date of stockholder approval.
• The Series B warrants include a 'zero exercise price' option, potentially leading to substantial dilution for existing stockholders.
• The offering is on a 'reasonable best efforts' basis, with no minimum amount required to be sold.
• Roth Capital Partners, LLC is acting as the exclusive placement agent.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of its product candidates.
• Concurrently with the issuance of the common stock, pre-funded warrants and common warrants, the company intends to issue to each Purchaser, in a private placement, Series C Warrants and Series D Warrants.

Sentiment

Score: 5

Explanation: Neutral sentiment. The announcement details a capital raise, which is generally positive, but the potential dilution from the warrants and the 'best efforts' nature of the offering introduce uncertainty.

Positives

• The offering aims to strengthen Aptevo's financial position, providing capital for working capital and general corporate purposes, including the further development of its product candidates.
• The company has engaged Roth Capital Partners, LLC, to act as our exclusive placement agent in connection with this offering.

Negatives

• The 'zero exercise price' option in the Series B warrants could lead to significant dilution for existing shareholders.
• The offering is on a 'reasonable best efforts' basis, meaning there's no guarantee of raising a specific amount.
• There is no established public trading market for the pre-funded warrants or common warrants, and we do not expect a market to develop.
• The Series A Warrants and the Series B Warrants are not exercisable until Stockholder Approval and may not have any value.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The 'zero exercise price' option in the Series B warrants could lead to significant dilution for existing shareholders.
• There is no guarantee that Stockholder Approval will ever be obtained.
• The Securities Purchase Agreement that we are entering into in connection with this offering does not contain a prohibition against short sales between the time of closing this offering and obtaining Stockholder Approval which may drive down the market price of our common stock ahead of obtaining Stockholder Approval.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including the further development of its product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Sixteen new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Existing shareholders face potential dilution due to the 'zero exercise price' option in the Series B warrants.
• New investors will be subject to immediate dilution in net tangible book value.
• The company aims to advance its clinical programs, potentially benefiting patients in the long term.

Next Steps

• Seek Stockholder Approval for the exercise of the Series A and Series B warrants.
• Close the public offering.
• Utilize the net proceeds for working capital and general corporate purposes, including the further development of product candidates.

Key Dates

Keywords

public offering, common stock, warrants, Aptevo Therapeutics, Series A warrants, Series B warrants, pre-funded warrants, Roth Capital Partners, dilution, stockholder approval